|
1
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Andrews L: Dietary flavonoids for the
prevention of colorectal cancer. Clin J Oncol Nurs. 17:671–672.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Altobelli E, Lattanzi A, Paduano R,
Varassi G and di Orio F: Colorectal cancer prevention in Europe:
Burden of disease and status of screening programs. Prev Med.
62:132–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sugarbaker PH: Colorectal cancer:
Prevention and management of metastatic disease. BioMed Res Int.
2014:7828902014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lieberman DA, Rex DK, Winawer SJ,
Giardiello FM, Johnson DA and Levin TR: Guidelines for colonoscopy
surveillance after screening and polypectomy: A consensus update by
the US Multi-Society Task Force on Colorectal Cancer.
Gastroenterology. 143:844–857. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Malafosse R, Penna C, Cunha Sa A and
Nordlinger B: Surgical management of hepatic metastases from
colorectal malignancies. Ann Oncol. 12:887–894. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dong-Xu W, Jia L and Su-Juan Z:
MicroRNA-185 is a novel tumor suppressor by negatively modulating
the Wnt/β-catenin pathway in human colorectal cancer. Indian J
Cancer. 52 Suppl 3:E182–E185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qiu Y, Liu Q, Chen G, Wang W, Peng K, Xiao
W and Yang H: Outcome of rectal cancer surgery in obese and
nonobese patients: A meta-analysis. World J Surg Oncol. 14:232016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Donadeu FX, Schauer SN and Sontakke SD:
Involvement of miRNAs in ovarian follicular and luteal development.
J Endocrinol. 215:323–334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rutnam ZJ and Yang BB: The involvement of
microRNAs in malignant transformation. Histol Histopathol.
27:1263–1270. 2012.PubMed/NCBI
|
|
16
|
Xie M, Qin H, Luo Q, Huang Q, He X, Yang
Z, Lan P and Lian L: MicroRNA-30a regulates cell proliferation and
tumor growth of colorectal cancer by targeting CD73. BMC Cancer.
17:3052017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang S, Yin WL, Zhang X and Zhang XY:
MicroRNA-455 is downregulated in gastric cancer and inhibits cell
proliferation, migration and invasion via targeting insulin-like
growth factor 1 receptor. Mol Med Rep. 16:3664–3672. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu PL, Liu WL, Chang JM, Chen YH, Liu YP,
Kuo HF, Hsieh CC, Ding YS, Chen WW and Chong IW: MicroRNA-200c
inhibits epithelial-mesenchymal transition, invasion, and migration
of lung cancer by targeting HMGB1. PLoS One. 12:e01808442017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang H, Yan T, Liu Z, Wang J, Lu Y, Li D
and Liang W: MicroRNA-137 is negatively associated with clinical
outcome and regulates tumor development through EZH2 in cervical
cancer. J Cell Biochem. 119:938–947. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ye L, Wang H and Liu B: miR-211 promotes
non-small cell lung cancer proliferation by targeting SRCIN1.
Tumour Biol. 37:1151–1157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miyoshi J, Toden S, Yoshida K, Toiyama Y,
Alberts SR, Kusunoki M, Sinicrope FA and Goel A: MiR-139-5p as a
novel serum biomarker for recurrence and metastasis in colorectal
cancer. Sci Rep. 7:433932017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim TH, Kim YK, Kwon Y, Heo JH, Kang H,
Kim G and An HJ: Deregulation of miR-519a, 153, and 485–5p and its
clinicopathological relevance in ovarian epithelial tumours.
Histopathology. 57:734–743. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen Z, Li Q, Wang S and Zhang J:
miR-485-5p inhibits bladder cancer metastasis by targeting HMGA2.
Int J Mol Med. 36:1136–1142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Anaya-Ruiz M, Bandala C and Perez-Santos
JL: miR-485 acts as a tumor suppressor by inhibiting cell growth
and migration in breast carcinoma T47D cells. Asian Pac J Cancer
Prev. 14:3757–3760. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lou C, Xiao M, Cheng S, Lu X, Jia S, Ren Y
and Li Z: MiR-485-3p and miR-485-5p suppress breast cancer cell
metastasis by inhibiting PGC-1α expression. Cell Death Dis.
7:e21592016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ding C, Luo J, Fan X, Li L, Li S, Wen K,
Feng J and Wu G: Elevated Gab2 induces tumor growth and
angiogenesis in colorectal cancer through upregulating VEGF levels.
J Exp Clin Cancer Res. 36:562017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ding C, Luo J, Yu W, Gao S, Yang L, Chen C
and Feng J: Gab2 is a novel prognostic factor for colorectal cancer
patients. Int J Clin Exp Pathol. 8:2779–2786. 2015.PubMed/NCBI
|
|
30
|
Matsumura T, Sugimachi K, Takahashi Y,
Uchi R, Sawada G, Ueda M, Hirata H, Sakimura S, Ueo H, Takano Y, et
al: Clinical significance of GAB2, a scaffolding/docking protein
acting downstream of EGFR in human colorectal cancer. Ann Surg
Oncol. 21 Suppl 4:S743–S749. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gu DH, Mao JH, Pan XD, Zhu H, Chen X,
Zheng B and Shan Y: microRNA-302c-3p inhibits renal cell carcinoma
cell proliferation by targeting Grb2-associated binding 2 (Gab2).
Oncotarget. 8:26334–26343. 2017.PubMed/NCBI
|
|
32
|
Xu LJ, Wang YC, Lan HW, Li J and Xia T:
Grb2-associated binder-2 gene promotes migration of non-small cell
lung cancer cells via Akt signaling pathway. Am J Transl Res.
8:1208–1217. 2016.PubMed/NCBI
|
|
33
|
Chen Y, Liu Q, Wu M, Li M, Ding H, Shan X,
Liu J, Tao T, Ni R and Chen X: GAB2 promotes cell proliferation by
activating the ERK signaling pathway in hepatocellular carcinoma.
Tumour Biol. 37:11763–11773. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang G, Zhou H, Xiao H, Liu Z, Tian H and
Zhou T: MicroRNA-92a functions as an oncogene in colorectal cancer
by targeting PTEN. Dig Dis Sci. 59:98–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gao F and Wang W: MicroRNA-96 promotes the
proliferation of colorectal cancer cells and targets tumor protein
p53 inducible nuclear protein 1, forkhead box protein O1 (FOXO1)
and FOXO3a. Mol Med Rep. 11:1200–1206. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rothschild SI: Epigenetic therapy in lung
cancer - Role of microRNAs. Front Oncol. 3:1582013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mou X and Liu S: MiR-485 inhibits
metastasis and EMT of lung adenocarcinoma by targeting Flot2.
Biochem Biophys Res Commun. 477:521–526. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jing LL and Mo XM: Reduced miR-485-5p
expression predicts poor prognosis in patients with gastric cancer.
Eur Rev Med Pharmacol Sci. 20:1516–1520. 2016.PubMed/NCBI
|
|
39
|
Guo GX, Li QY, Ma WL, Shi ZH and Ren XQ:
MicroRNA-485-5p suppresses cell proliferation and invasion in
hepatocellular carcinoma by targeting stanniocalcin 2. Int J Clin
Exp Pathol. 8:12292–12299. 2015.PubMed/NCBI
|
|
40
|
Sun X, Liu Y, Li M, Wang M and Wang Y:
Involvement of miR-485-5p in hepatocellular carcinoma progression
targeting EMMPRIN. Biomed Pharmacother. 72:58–65. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Formosa A, Markert EK, Lena AM, Italiano
D, Finazzi-Agro' E, Levine AJ, Bernardini S, Garabadgiu AV, Melino
G and Candi E: MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c,
miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p,
mapped to the 14q32.31 locus, regulate proliferation, apoptosis,
migration and invasion in metastatic prostate cancer cells.
Oncogene. 33:5173–5182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wu J, Li J, Ren J and Zhang D:
MicroRNA-485-5p represses melanoma cell invasion and proliferation
by suppressing Frizzled7. Biomed Pharmacother. 90:303–310. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lin XJ, He CL, Sun T, Duan XJ, Sun Y and
Xiong SJ: hsa-miR-485-5p reverses epithelial to mesenchymal
transition and promotes cisplatin-induced cell death by targeting
PAK1 in oral tongue squamous cell carcinoma. Int J Mol Med.
40:83–89. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kang M, Ren MP, Zhao L, Li CP and Deng MM:
miR-485-5p acts as a negative regulator in gastric cancer
progression by targeting flotillin-1. Am J Transl Res. 7:2212–2222.
2015.PubMed/NCBI
|
|
45
|
Yart A, Mayeux P and Raynal P: Gab1, SHP-2
and other novel regulators of Ras: Targets for anticancer drug
discovery? Curr Cancer Drug Targets. 3:177–192. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gu H and Neel BG: The ‘Gab’ in signal
transduction. Trends Cell Biol. 13:122–130. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lee SH, Jeong EG, Nam SW, Lee JY, Yoo NJ
and Lee SH: Increased expression of Gab2, a scaffolding adaptor of
the tyrosine kinase signalling, in gastric carcinomas. Pathology.
39:326–329. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Duckworth C, Zhang L, Carroll SL, Ethier
SP and Cheung HW: Overexpression of GAB2 in ovarian cancer cells
promotes tumor growth and angiogenesis by upregulating chemokine
expression. Oncogene. 35:4036–4047. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fleuren ED, O'Toole S, Millar EK, McNeil
C, Lopez-Knowles E, Boulghourjian A, Croucher DR, Schramek D,
Brummer T, Penninger JM, et al: Overexpression of the oncogenic
signal transducer Gab2 occurs early in breast cancer development.
Int J Cancer. 127:1486–1492. 2010. View Article : Google Scholar : PubMed/NCBI
|
